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Introduction
Replication-defective recombinant adenoviral vectors have been used to augment the efficiency of arterial gene transfer. Experiments performed in vitro have resulted in transduction efficiencies of up to 88% of cultured endothelial cells. 1 Consistent transduction of endothelial 2 and smooth muscle cells (SMCs) 3, 4 has also been achieved in vivo. In this setting, high transfection efficiencies (in the range of 30% of medial SMCs) 3, [5] [6] [7] have been achieved using intraoperative gene delivery. However, when strictly percutaneous catheter gene delivery has been used, the efficiency of gene transfer to medial SMCs, although higher with adenoviral vectors than with any other vector, has remained consistently lower, below 10%. [8] [9] [10] [11] [12] Such low efficacy may hamper clinical application of arterial gene therapy, in particular, in those applications such as the prevention of intimal hyperplasia after arterial injury in which medial SMCs are an important target.
Previous studies 2, 12, 13 have suggested that the endothelium and internal elastic lamina (IEL) may act as barriers to successful medial transfection with adenoviral vectors. If gene delivery is to be applied to treat vascular disease, however (eg for the prevention of restenosis), the endothelial layer may not limit the efficacy of gene transfer since it is consistently removed at the time of balloon inflation during angioplasty 14 or at the time of delivery. 12, 15, 16 Thus, the major barrier to percutaneous adenovirus-mediated gene delivery to the arterial media appears to be the IEL.
Since elastin is a major component of the IEL, pre-incubation with elastase may permeate the IEL to adenoviral recombinant vectors and therefore enhance the efficiency of medial transduction, a critical step for many arterial gene therapy strategies. Accordingly, the present study was designed to assess the effect of elastase pre-treatment of the IEL on the feasibility, efficiency and safety of in vivo adenovirus-mediated gene transfer to the media via an exclusively percutaneous approach.
Results
Summary of in vivo elastase treatment and gene transfer experiments A total of 54 rabbits and 108 arteries were studied. Fortyone animals (group 1) were used for the dose ranging pilot study to determine the highest elastase concentration that induced no detectable damage to the IEL and the media, using angiography, light microscopic and ultrastructural study, at 3 days and 7 weeks following elastase pre-treatment.
To test whether elastase enhanced arterial gene transfer 1024 in vivo, AdRSV-␤gal was delivered in both iliac arteries in 10 rabbits after endothelial abrasion (group 2). In each animal, each iliac artery was randomly assigned to pretreatment with either elastase or saline. For further quantitative evaluation of transfer efficiency, AdCmv-luc was delivered in both iliac arteries in three rabbits using the same method (group 3).
Elastase dose ranging pilot study (group 1)
The highest elastase dose used in this experiment (2.625 IU) led to macroscopically and angiographically visible aneurysmal dilatation of the iliac artery. Microscopic examination showed complete abrasion of the endothelium and necrosis of both the IEL and the media. Lower doses (2 × 10 −2 IU and 2 × 10 −3 IU) also induced aneurysm formation. Microscopic examination found IEL disruption with extensive necrosis to the superficial half of the media. Aneurysms were not observed after incubation with 2 × 10 −4 IU, however, light microscopic examination disclosed IEL disruption and necrosis of the superficial layers of the media. The IEL was microscopically preserved at 2 × 10 −5 IU, but necrosis of the two or three innermost SMC layers of the media was frequently observed. Small areas of SMC necrosis, limited to the superficial layer, were observed at 2 × 10 −6 IU. However, at 2 × 10 −7 IU, elastase did not evoke vascular injury, as assessed by angiographic, macroscopic, light microscopic and ultrastructural examination.
At this dosage, no evidence of injury to the arterial wall was observed 3 days ( Figure 1 ) following elastase pretreatment either on gross or light microscopic examination. The continuity of the internal elastic membrane and the integrity of the underlying tunica media were always preserved and there was no evidence of inflammation on morphological examination by light microscopy of the treated vessels as compared with the control vessels. Using the appropriate staining, there was no evidence for lymphocyte, macrophage or PMNs infiltrates either early (day 3) or late (7 weeks) following elastase treatment. In addition, there was no evidence of tissue edema, connective tissue dissociation, increase in tissue thickness or cellular necrosis. On ultrastructural study (Figure 2 ), the intima was thin, and most of the endothelium was removed and replaced by occasional cell remnants. The IEL was an intact continuous thick elastic fiber. The medial smooth muscle cells showed no alterations and were enmeshed in a normal extra cellular matrix network made of collagen and elastic fibers. The external elastic lamina and adventitia were normal. Likewise, after 7 weeks, macroscopic and light microscopic examination found neither dilation nor aneurysms, but rather neointimal formation and a normal IEL and media (Figure 3 ). Gross and light microscopic examination of tissue samples from liver, brain, testes, heart, lungs, kidneys, limb skeletal muscle and arterial segments adjacent to the treated arterial site failed to show any tissue damage 3 days as well as 7 weeks following elastase pre-treatment. Both at 3 days and 7 weeks following pretreatment with elastase (2 × 10 −7 IU) or saline, no vessel dilatation or aneurysms were observed and lumen diameters did not significantly differ between groups (3 days: 2.4 ± 0.2 versus 2.3 ± 0.3 mm, P = NS; 7 weeks: 2.1 ± 0.3 versus 2.2 ± 0.5 mm, P = NS) (Figure 4 ). At 7 weeks, mild intimal thickening was observed in both groups, as expected following balloon abrasion of the endothelium, but the intima/media ratio was similar between groups (0.62 ± 0.22 in saline-treated arteries and 0.64 ± 0.3 in elastase-treated areries, NS). Likewise, there was no difference in the area circumscribed by the external elastic lamina. This latter result is consistent with the absence of angiographic luminal enlargement observed 7 weeks after elastase treatment with reference to saline-treated vessels (4.1 ± 0.7 versus 4.3 ± 0.8 mm 2 respectively, NS). Finally, there was no difference in intimal areas between groups, 0.37 ± 0.28 mm 2 in saline-treated arteries and 0.39 ± 0.3 in elastase-treated areries, NS).
Transfection efficiency at 3 days: morphometric analysis (group 2) Three days following transfection, X-gal staining showed nuclear specific staining in only five of 10 treated arteries after preincubation with saline as compared with success- ful transfection of all (10/10) elastase-pretreated vessels (P Ͻ 0.04). Macroscopic examination after X-gal staining revealed a mottled, heterogeneous staining of the luminal aspect of the artery, always confined to the area delimited by the balloons. On light microscopic analysis, there was consistent endothelium denudation. Nuclear staining was located below an intact IEL, in sparse medial cells, identified by immunohistochemistry as SMCs ( Figure 5 ). Morphometric analysis showed that in elastase pretreated arteries (n = 1440 sections), 1.0 ± 0.3% (range 0-3.2) of medial cells, representing 7.2 ± 2.5 cells per arterial section, expressed the transgene. In contrast, in saline pre-treated arteries (n = 1440 sections), only 0.3 ± 0.1% (range 0-0.9) of medial cells, representing 2.3 ± 0.9 cells per arterial section, showed evidence of nuclear ␤-galactosidase activity. Therefore, the percentage as well as the absolute number of transfected cells in the media were significantly higher in elastase than in saline pretreated arteries (P = 0.003 for both) ( Figure 6 ). The distribution of transfected cells was heterogeneous, some arterial cross-sections being entirely devoid of staining. In one artery, transgene expression was also found in the adventitia, located in the endothelial and SMCs of the vasa-vasora. The mean total number of cells per section in elastase pre-treated arteries (940 ± 87) remained the same as in saline-treated arteries (922 ± 93), NS.
Transfection efficiency at day 3: chemiluminescence analysis (group 3) Seventy-two hours after transfection with AdCmv-luc, luciferase activity was detected in all vessels, pre-treated with saline (n = 3) or elastase (n = 3). However, transgene expression was 1.9-fold higher in elastase pre-treated than in saline pre-treated arteries (70 ± 32 versus 36 ± 15 pg luciferase/mg tissue, P = 0.03) (Figure 7) . The mean weight of arterial segments did not differ among groups, being 88 ± 8 mg in the saline-treated arteries versus 92 ± 10 mg in the elastase-treated arteries, P = NS.
Discussion
Adenoviral vectors are efficient vectors for arterial gene transfer. However, even with these vectors, the efficiency of gene transfer to medial smooth muscle cells remains limited. Using various delivery systems, previous investigators have achieved transduction rates in the media consistently below 10% when strictly percutaneous delivery has been attempted (eg without surgical ligation of side branches). 12, [15] [16] [17] [18] In addition, while these results were obtained in normal arteries, transfer efficiency is markedly reduced in atherosclerotic vessels, 16 a potential caveat for adenovirus-mediated gene therapy. 19 Medial smooth muscle cells play a key role in response to injury and these cells are an important target for arterial gene therapy, specifically for the prevention of restenosis after angioplasty. Recent arterial gene transfer studies have suggested that the relatively low transfection efficiency characteristic of nonviral vectors may be sufficient to generate meaningful biological effects when the transgene encodes for a secreted protein. [20] [21] [22] However, for genes encoding proteins which remain intracellular, such as the Gax (growth arrest homeobox), 23, 24 hirudin, 25 p21 26 or retinoblastoma gene products, 5 more efficient transfection will likely be required.
Previous work 2,12,13 has suggested that the endothelium and IEL may be the main barriers to adenovirusmediated gene transfer to the media. We have previously shown, using percutaneous delivery of adenoviral vectors, that de-endothelialization improves SMC transfection with a DBC, but that medial transfection rates remain low. 12 We sought to evaluate the extent to which controlled incubation of the IEL with elastase, following endothelial abrasion, may enhance the efficiency of medial transduction by adenoviral recombinant vectors. Our findings indicate that: (1) incubation of the vessels with elastase before delivery of adenoviral vectors significantly increased the efficiency of medial transfection; (2) the elastase regimen used in this study did not appear to be associated with either microscopic or ultrastructural damage to the IEL or the arterial wall; and (3) The IEL appeared indeed to be an important barrier to medial transfection by adenoviral vectors.
The ability to achieve high efficiency of transduction based on adenovirus-mediated gene transfer represents a
27 A 30-min exposure is necessary to achieve substantial transfection using passive diffusion delivery devices with adenoviral vectors. 12, 13, 15 Elastin is a major component of the vascular wall and acts to distribute stress throughout the wall. The elastic tissue forms a network of fibers and lamellae within the vascular wall, characterized by a three-dimensional architecture. The internal elastic lamina adjacent to the endothelium has a scalloped appearance with small gaps or fenestrae scattered throughout this sheet. 28 Most of the openings of the fenestrae are bridged by fine elastic fibers that give the fenestrae a sieve-like appearance. Despite improvement in transfection efficiency after elastase incubation, neither light nor electron microscopic abnormalities of the principal sheet of the internal elastic lamina were seen. This suggests that elastase, at the concentrations used, may degrade the fine elastic fibers occluding the gaps rather than the condensed elastin fibers constituting the principal sheet itself. This may in turn open breaches or holes between the elastin mesh without actual degradation of the condensed sheet, resulting in improved penetration of adenoviral vectors into the media. This hypothesis is supported by the fact that both 3 days and 7 weeks post-procedure no vessel dilation or aneurysms were observed and there was no increase in lumen diameters.
The double balloon catheter is not an angioplasty catheter. The latter usually induces disruption of the elastic laminae and balloon angioplasty differs from endothelial balloon abrasion. This represents a limitation of the study. However, the transduction efficiency observed in the present experiments is somewhat akin to results observed in the clinical setting by Latinen et al, 29 in which adenovirus-mediated gene delivery was performed in the lower limb of patients with critical ischemia following percutaneous arterial angioplasty. The gene transfer efficiency varied between 0.006 and 0.07% of the arterial cells, and gene transfer was in fact observed in only four of six transfected arteries. These data appear consistent with the hypothesis that prior vessel trauma by an angi-c b a d
Figure 5 Typical X-gal staining of rabbit iliac arteries showing ␤-galactosidase activity 3 days after adenovirus-mediated transfer of the nlslacZ gene in vivo using the double balloon technique with previous de-endothelialization. (a) Abraded saline pre-treated artery; macroscopic view of the luminal aspect of the artery. (b) Light microscopic appearance of (a) after frozen section. (c) Injured elastase pre-treated artery (2 × 10 −7 IU). Note the heterogeneous distribution of X-gal staining. (d) Light microscopic appearance of (c) after frozen section. Microscopic examination of the transfected sites confirmed consistent endothelium denudation, while continuity of the internal elastic membrane (white arrowheads) and the integrity of the underlying tunic media (black arrows) were consistently preserved.
oplasty balloon may not be sufficient to achieve satisfactory transfer.
It is well known that even in segments that are devoid of angiographically-visible side branches, the space delimited by the two balloons can contain collateral branches constituting potential sources of dissemination of elastase. However, complete neutralization of elastase is achieved in flowing blood by the circulating inhibitor, alpha anti-trypsin, in less than 1 s. 30 Therefore, the elastase regimen used in this study appears safe both at the site of transfection as well as in other organs.
Elastase pre-treatment increases transduction efficiency in the media during percutaneous catheter delivery of recombinant adenoviral vector and does not lead to detectable arterial damage. These results may have a substantial impact on delivery techniques procedures for adenovirus-mediated arterial gene therapy.
Materials and methods
Elastase Pure pancreatic pig elastase was used (pancreatic porcine elastase ultra pure grade, BI 007024, Elastase Biosys 20 mg; Columbia, MD, USA). Elastase powder was stored in 1 mg aliquots at −20°C and then diluted in saline just before intervention (1 mg = 17.5 IU). Elastase solutions are stable at pH 8. The main plasma inhibitor of pancreatic porcine elastase is alpha anti-trypsin (AAT), which is found in the plasma at high concentrations (2 g/l).
AAT is a strong and irreversible inhibitor of elastase. Complete neutralization of pancreatic porcine elastase or leukocyte elastase is achieved in flowing blood in less than 1 s. 30 A pilot experiment (group 1) was designed to determine the highest elastase concentration that induced no damage to the IEL and the media after a 5 min incubation in previously denuded external iliac arteries via a 4 F double-balloon catheter (DBC) (Mansfield Medical, Boston Scientific Corporation, MA, USA). For all others animals (groups 2 and 3), each iliac artery was randomly assigned to pre-treatment with either elastase or a control infusion of saline.
Recombinant adenoviral vectors
Replication-defective recombinant adenoviral vectors, based on human adenovirus 5 serotype, were produced as previously described. [31] [32] [33] AdRSV-␤gal contains the Escherichia coli lacZ gene and the SV40 early region nuclear localization sequence (nls). NlslacZ gene encodes a nuclear-targeted ␤-galactosidase under the control of the Rous sarcoma virus promoter. Another E1-deleted recombinant adenovirus referred to as AdCmv-luc was used in this study (a gift from Dr JJ Robert, CNRS-UMR 9923, Paris, France). AdCmv-luc encodes the firefly luciferase gene driven by the enhancer/promoter of the immediate-early gene of human cytomegalovirus. The Cmv-luc cassette inserted in the adenoviral vector construct was derived from the expression vector pUT 650 (CAYLA, Toulouse, France). Adenoviral stocks were thawed 15 min before use. To prevent variations in transfer efficiency related to variations between stocks, only one viral stock was used for all the experiments performed with each adenoviral vector.
Elastase pre-treatment Preincubation (with elastase or saline) was performed in the external iliac arteries of New Zealand White rabbits. Anesthesia was induced with intramuscular acepromazine and maintained with intravenous pentobarbital. All animal procedures were approved by the Institutional Animal Care and Use Committees.
A 4F angiography catheter was introduced through the right carotid artery over a 0.014 inch guide-wire under fluoroscopic guidance and advanced into the abdominal aorta. A 4 French DBC was inserted after a baseline angiogram. The distal balloon was inflated in the femoral artery, and then withdrawn, to achieve endothelial abrasion while avoiding damage to SMCs. The DBC was advanced to the iliac artery and positioned in a segment lacking angiographically-visible side branches. The two balloons were inflated, thereby isolating a transfection chamber, which was washed with saline. Elastase (in 300 l saline) was infused for 5 min in the previously denuded external iliac artery segment via the infusion port of the DBC. Therefore, elastase was not in contact with flowing blood, which contains high concentrations of the elastase inhibitor AAT. The two balloons were then deflated and the DBC dead space as well as the artery were washed with saline.
A dose ranging pilot study (group 1) was performed to determine the highest concentration of elastase that produced neither angiographically detectable aneurysms nor increases in the lumen diameter, or light microscopically detectable damage to the IEL or the media. The initial dose of 2.625 IU was chosen after literature review and doses were decreased logarithmically until the safest dosage was identified. 34, 35 Additional experiments were performed at this dose. In two animals, ultrastructural analysis was performed using electron microscopy. These animals were killed immediately after preincubation with saline on one side and elastase pre-treatment on the other side. Fifteen-mm long segments of iliac arteries were removed, washed in PBS for 5 min, and immersion-fixed in a 2.5% solution of glutaraldehyde in PBS at pH 7.4, for 4 h, and rinsed in PBS. From each segment, four arterial rings were pro-cessed for routine electron microscopy by fixation with osmium tetroxide, epon embedding and toluidine blue staining of semithin sections. Thin sections were cut and counter stained with lead citrate and uranyl acetate, and observed with a Zeiss (Oberkochen, Germany) EM 10 electron microscope. In four animals toxicity after 7 weeks was investigated by angiography and ligth microscopy. After orcein-hematoxylin-safranin staining, 12 evenly spaced sections from the arterial segments subjected to incubation were analysed by morphometry by use of the Biocom 200 image analysis system with a dialux 20EB microscope (Leitz, Wetzlar, Germany), a charge-coupled device (CDC) camera and the Histo software Biocom. In 14 animals, systemic toxicity was investigated in organs remote from the elastase-treated site, including liver, brain, testes, heart, lungs, kidneys, limb skeletal muscle and adjacent arterial segments, 3 days (n = 10) and 7 weeks (n = 4) following elastase pretreatment. For each specimen, at least three different segments were obtained, embedded in paraffin, and cut into five sections. Sections were counter-stained with hematoxylin and eosin, and examined by light microscopy.
Angiographic analysis
Angiograms were performed after intra-arterial injection of 200 g of nitroglycerin and interposition of a calibrated grid for computation of the enlargement factor (Namic Medical Systems, Toledo, OH, USA). These angiograms were obtained before preincubation of the vessel with elastase or saline, and repeated immediately before animals were killed. Measurements of luminal diameter of both iliac arteries were then performed.
Gene transfer experiments
AdRSV-␤gal (5.9 × 10 9 plaque forming units (p.f.u.) in 300 l phosphate-buffered saline (PBS) , group 2) or AdCmv-luc (5 × 10 9 p.f.u. in 300 l PBS, group 3) were transferred into both previously denuded external iliac arteries after incubation with either elastase or saline, using the DBC. The viral solution was instilled within the 15-mm long arterial segment isolated by the two inflated balloons and incubated for 30 min.
Detection of lacZ expression in the arterial wall Three days following transfection, animals (group 2, n = 10) were killed by pentobarbital overdose. To assess nlslacZ gene expression, the arteries were harvested and stained with X-gal reagent (Sigma, St Louis, MO, USA) for 2 h, at 37°C, as previously described.
36 Arterial segments were then mounted in OCT compound (Miles Laboratories, Elkhart, IN, USA) for cryosectioning, cut into 5-m sections, and counter-stained with hematoxylin and eosin or Richardson's elastic trichrome. Expression of the nlslacZ gene was considered positive only when dark blue staining of the nucleus was observed. To determine which cell types within the arterial wall expressed the transgene, immunohistochemical staining of X-galstained arterial sections was performed, using a mouse monoclonal anti-␣-actin primary antibody specific for vascular smooth muscle (HHF-35, Enzo Diagnostics, Farmingdale, NY, USA), and then a polyclonal peroxidaselabeled anti-mouse immunoglobulin G secondary antibody (Signet Laboratories, Dedham, MA, USA).
Quantification of lacZ expression in the arterial wall Transgene expression 3 days after delivery was quantified using morphometric analysis in 10 animals (group 2). For each transfected iliac artery, six serial 2-mm long segments were taken from the target zone. From each artery, 144 evenly spaced sections were examined by light microscopy after X-gal staining, by two operators blinded to treatment allocation. Transfection efficiency was determined by counting stained versus total medial nuclei in each arterial section.
Detection of luciferase expression in the arterial wall In three animals (group 3), transgene expression after AdCmv-luc delivery was quantified using a chemiluminescent assay (Luciferase assay system; Promega, Madison, WI, USA) in tissue extracts prepared from iliac arteries, as previously described. 37, 38 Briefly, 3 days following transfection the animals were killed by pentobarbital overdose. The iliac arteries were removed, washed in PBS at 4°C, then homogenized in 1 ml cell lysis reagent (Promega) using a Tekmar tissuemizer for 1 min. The resulting mixture was spun for 5 min to pellet large debris. A 20 l aliquot was mixed at room temperature with 100 l of luciferase assay reagent (Promega) containing beetle luciferin. Emission of light, integrated over 10 s, was measured with a luminometer (Lumat LB 9501, Berthold, Nashua, NH, USA). The assay was calibrated with a standard curve generated using purified firefly luciferase (Boehringer Mannheim, Indianapolis, IN, USA). The calibration curve was linear from 10
(10 pg/l) to 10 −8 (1 mg/l). Results, expressed in relative light units (RLU), were within the linear range of the detection system. All reactions were performed on five samples and the mean value of the five experiments was used as a measure of total luciferase activity per vessel. Transfection efficiency was expressed in picogrammes of luciferase protein normalized for tissue weight.
Statistical analyses
Values are expressed as mean ± standard error of the mean (m ± s.e.m.).
2 analysis was used to compare the percentage of transfected arteries using AdRSV-␤gal between groups. Each animal being its own control, comparisons involving continuous variables used two-tailed paired Student's t tests. A value of P Ͻ 0.05 was considered statistically significant.
